Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC28A1 | O00337 | 1/20 | 0.52 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.52 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.52 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.52 |
| ▸ | CDA | P32320 | 1/20 | 0.52 |
| ▸ | P2RY2 | P41231 | 10/20 | 0.43 |
| ▸ | AHCY | P23526 | 3/20 | 0.42 |
| ▸ | EZH2 | Q15910 | 1/20 | 0.42 |
| ▸ | P2RY6 | Q15077 | 8/20 | 0.41 |
| ▸ | P2RY4 | P51582 | 3/20 | 0.40 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12280146 | 1.00 | SLC28A1 (0.52) | SLC28A1SLC28A2SLC29A1SLC28A3CDA | |
| SCHEMBL22902119 | 0.87 | SLC28A1 (0.48) | SLC28A1SLC28A2SLC29A1SLC28A3CDA | |
| SCHEMBL22902099 | 0.87 | SLC28A1 (0.48) | SLC28A1SLC28A2SLC29A1SLC28A3CDA | |
| SCHEMBL29905573 | 0.87 | SLC28A1 (0.48) | SLC28A1SLC28A2SLC29A1SLC28A3CDA | |
| SCHEMBL22902109 | 0.87 | SLC28A1 (0.48) | SLC28A1SLC28A2SLC29A1SLC28A3CDA | |
| SCHEMBL22902118 | 0.87 | SLC28A1 (0.48) | SLC28A1SLC28A2SLC29A1SLC28A3CDA | |
| SCHEMBL22902120 | 0.84 | SLC28A1 (0.45) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL22902108 | 0.84 | SLC28A1 (0.45) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL29905588 | 0.84 | SLC28A1 (0.45) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL29905547 | 0.81 | SLC28A1 (0.43) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250111889-A1 | DE NOVO DESIGNED MACROCYCLIC OLIGOAMIDES | UNIVERSITY OF WASHINGTON | 2025-04-03 | — | — | US | disclosed |
| CN-115926102-B | Polyurethane crosslinking modified gelatin medical hydrogel based on imino bonds, and preparation method and application thereof | 赛克赛斯生物科技股份有限公司 | 2025-03-25 | — | — | CN | disclosed |
| CN-115926102-A | Polyurethane cross-linked modified gelatin medical hydrogel based on imine bond and preparation method and application thereof | 赛克赛斯生物科技股份有限公司 | 2023-04-07 | — | — | CN | disclosed |
| WO-2021011572-A1 | ENHANCING THE ANTIVIRAL EFFICACY OF RNA VIRUS INHIBITION BY COMBINATION WITH MODULATORS OF PYRIMIDINE METABOLISM | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2021-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250111889-A1 | DE NOVO DESIGNED MACROCYCLIC OLIGOAMIDES | DHFR, CCNH, ODC1 | SLC28A1 4003/4885SLC28A2 3638/4885SLC29A1 2824/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.